FREE Shipping on all US Orders
A new drug blocks DHT at the scalp — not in the body. That distinction is everything.
Clascoterone — a topical DHT blocker — produced 539% relative improvement in hair count vs placebo in a 1,465-patient trial. It works by blocking DHT at the follicle receptor, locally, without entering systemic circulation. No sexual side effects. No hormonal disruption. This is the first new mechanism in hair loss treatment in decades — and it is the same mechanism that topical botanical DHT inhibitors have always used.
Finasteride works systemically — it reduces DHT throughout the entire body. Clascoterone works locally — it blocks DHT at the follicle receptor specifically. The result is a drug that addresses the primary driver of androgenetic alopecia without the systemic hormonal consequences that have limited finasteride's use. The topical route was always the right route. The pharmaceutical industry just confirmed it.
For thirty years, the pharmaceutical approach to androgenetic alopecia has relied on one systemic DHT-blocking drug: finasteride. It works by inhibiting 5-alpha reductase throughout the body — reducing DHT production systemically, which reduces DHT at the follicle, which slows the miniaturisation process. It is effective. It is also contraindicated in women of reproductive age, produces sexual side effects in a meaningful proportion of users, and requires continuous use — because the DHT reduction is systemic and disappears when the drug is stopped.
The drug's systemic nature was never the goal. It was the consequence of the delivery route. What researchers always wanted was to block DHT at the follicle specifically — locally, without affecting systemic hormone levels. The technology to do that topically, at therapeutic concentration, simply did not exist in pharmaceutical form when finasteride was developed.
Cosmo Pharmaceuticals just demonstrated that it does now.
Clascoterone — a topical androgen receptor blocker applied directly to the scalp — showed 539% relative improvement in hair count compared to placebo in Scalp 1, and 168% in Scalp 2, across 1,465 men. If approved, it would be the first scalp treatment that works by blocking DHT right at the hair follicle — the first of its kind made specifically for male hair loss. The topical route was always the right route. The pharmaceutical industry has just confirmed it with the largest trial data set ever produced for a topical DHT blocker.
The Mechanism
Why local DHT blockade is different — and better — than systemic.
DHT drives androgenetic alopecia by binding to androgen receptors in genetically susceptible follicles — specifically the dermal papilla cells, which respond to DHT by producing the miniaturisation signals that shorten the anagen phase and progressively reduce follicle size. The target is always the androgen receptor in the follicle. Finasteride reaches it by reducing systemic DHT production. Clascoterone reaches it by blocking the receptor directly at the follicle.
The distinction has three significant clinical consequences:
Finasteride reduces DHT throughout the body — in the scalp, in the prostate, in the bloodstream, in every tissue that responds to DHT. The sexual side effects that affect an estimated 2–8% of users occur because DHT is suppressed systemically, including in tissues where DHT serves important functions. Clascoterone blocks the androgen receptor locally — at the follicle — without reducing systemic DHT. The follicle doesn't receive the DHT signal. Everything else continues receiving it normally.
This is not a marginal improvement on finasteride's side effect profile. It is a mechanistically different approach that eliminates the source of those side effects entirely.
Finasteride is contraindicated in women of reproductive age due to teratogenic risk — it is a category X drug in pregnancy. Female hair loss is predominantly driven by relative androgen excess and receptor sensitivity rather than absolute DHT elevation, making the systemic 5-alpha reductase inhibition model poorly suited to women's biology. Clascoterone's local androgen receptor blockade is mechanistically more appropriate for female pattern hair loss — addressing sensitivity at the receptor level without systemic hormonal consequences.
The current trials enrolled men. Female trials are the logical next step — and the perimenopausal women who represent the majority of those affected by hair loss are the population most likely to benefit from a topical receptor blocker over a systemic DHT suppressor.
The scalp permeability research we covered this week confirms that the scalp is a highly absorptive surface — topically applied compounds reach the follicle through both the follicular route and transdermal absorption into the dermal vascular network. A compound designed to block the androgen receptor, applied topically to the scalp daily, is delivering its effect precisely where it is needed — not throughout the body.
Topical delivery is not a compromise form of pharmaceutical delivery. For follicle-targeted treatment, it is the optimal form. The clascoterone results confirm this at a scale that no previous topical treatment trial has reached.
The Botanical Parallel
The topical DHT inhibition that has always been available.
Clascoterone is a synthetic androgen receptor antagonist. The mechanism — blocking DHT's interaction with the androgen receptor at the follicle, delivered topically — is new in pharmaceutical form. It is not new in botanical medicine.
Several botanical compounds have demonstrated 5-alpha reductase inhibition or androgen receptor modulation in peer-reviewed research, delivered topically at therapeutic concentration:
The clascoterone mechanism — topical DHT blockade at the receptor — is the pharmaceutical expression of what botanical formulation has always attempted through the topical route. The difference is specificity: clascoterone is a targeted synthetic receptor antagonist. The botanicals achieve similar outcomes through 5-alpha reductase inhibition upstream and through complementary mechanisms that address the full biological cascade rather than a single receptor.
The clascoterone trials measured hair count. They addressed the DHT pathway specifically. They did not address the five other simultaneous drivers of androgenetic alopecia that this month's research has mapped: PIILIF inflammation, microbiome dysbiosis, collagen structural decline, circadian rhythm disruption, ferritin depletion, or the mechanical pulling mechanism.
A drug that blocks DHT at the follicle with 539% relative efficacy is addressing one of six primary drivers — more precisely than anything available before it. The other five drivers continue. The case for a multi-mechanism daily botanical ritual alongside pharmaceutical DHT blockade — addressing what the drug cannot reach — becomes stronger with every new single-target pharmaceutical that confirms how complex the biology is.
What the clascoterone result means for how we think about hair loss treatment.
The 539% result is not just a clinical efficacy number. It is a proof of concept for topical treatment as the optimal route for follicle-targeted therapy. It confirms that what reaches the follicle through the scalp surface — whether pharmaceutical or botanical — can produce effects that systemic delivery cannot match for follicle specificity.
Every botanical active in the Laritelle formula reaches the follicle through the same topical route that clascoterone's 1,465-patient trial has now validated. The bhringaraj and nettle inhibiting 5-alpha reductase locally. The rosemary upregulating IGF-1 at the follicle. The patchouli reducing perifollicular inflammation. The green tea protecting the collagen matrix from oxidative damage. All of it delivered through the scalp surface — the route the clascoterone result has just confirmed as the right one.
The pharmaceutical field is arriving at what botanical topical formulation has always understood. The delivery route is correct. The local mechanism is correct. The daily consistency is correct. The missing piece — then and now — is addressing the full cascade, not just the DHT pathway.
1,465 patients just confirmed it.
Topical DHT inhibition. Available today.
Bhringaraj, nettle, and saw palmetto — each addressing the DHT pathway through the same topical route clascoterone just validated at scale. Daily, at therapeutic concentration, alongside everything else the formula addresses.
→ Explore the Fertile Roots CollectionScience, ritual, and botanical intelligence — delivered daily.
Each morning, one article. New research, ancient wisdom, and the honest science of hair and scalp health. Written for women who want to understand what is happening — not just what to buy.
By subscribing you agree to receive email from Laritelle Organic. Unsubscribe at any time.